Food and Drug Administration

Oncologic Drugs Advisory Committee

February 27, 2002

Briefing Information

Isses in the Clinical Development of Investigational Agents Being Evaluated for the Post-Surgical Adjuant Treatment of High-Risk (Stages IIb and III)  Melanoma   pdf   htm   doc

Bibliography   pdf    doc

Appropriate Study Design and Control for the Proposed Phase 3 Trial of
Investigational New Drug (IND) 2885, Melacine® (melanoma vaccine),
Corixa Corporation, for adjuvant treatment of melanoma   pdf

Bibliography   pdf   htm  doc